Literature DB >> 18952711

Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Shoshana Yakar1, Clifford J Rosen, Mary L Bouxsein, Hui Sun, Wilson Mejia, Yuki Kawashima, Yingjie Wu, Kelly Emerton, Valerie Williams, Karl Jepsen, Mitchell B Schaffler, Robert J Majeska, Oksana Gavrilova, Mariana Gutierrez, David Hwang, Patricia Pennisi, Jan Frystyk, Yves Boisclair, John Pintar, Héctor Jasper, Horacio Domene, Pinchas Cohen, David Clemmons, Derek LeRoith.   

Abstract

Serum insulin-like growth factor (IGF) -1 is secreted mainly by the liver and circulates bound to IGF-binding proteins (IGFBPs), either as binary complexes or ternary complexes with IGFBP-3 or IGFBP-5 and an acid-labile subunit (ALS). The purpose of this study was to genetically dissect the role of IGF-1 circulatory complexes in somatic growth, skeletal integrity, and metabolism. Phenotypic comparisons of controls and four mouse lines with genetic IGF-1 deficits-liver-specific IGF-1 deficiency (LID), ALS knockout (ALSKO), IGFBP-3 (BP3) knockout, and a triply deficient LID/ALSKO/BP3 line-produced several novel findings. 1) All deficient strains had decreased serum IGF-1 levels, but this neither predicted growth potential or skeletal integrity nor defined growth hormone secretion or metabolic abnormalities. 2) IGF-1 deficiency affected development of both cortical and trabecular bone differently, effects apparently dependent on the presence of different circulating IGF-1 complexes. 3) IGFBP-3 deficiency resulted in increased linear growth. In summary, each IGF-1 complex constituent appears to play a distinct role in determining skeletal phenotype, with different effects on cortical and trabecular bone compartments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952711      PMCID: PMC2653987          DOI: 10.1096/fj.08-118976

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  64 in total

Review 1.  Use of mutagenesis to probe IGF-binding protein structure/function relationships.

Authors:  D R Clemmons
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

Review 2.  Cellular actions of the insulin-like growth factor binding proteins.

Authors:  Sue M Firth; Robert C Baxter
Journal:  Endocr Rev       Date:  2002-12       Impact factor: 19.871

Review 3.  The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system.

Authors:  Y R Boisclair; R P Rhoads; I Ueki; J Wang; G T Ooi
Journal:  J Endocrinol       Date:  2001-07       Impact factor: 4.286

4.  Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo.

Authors:  Mary L Bouxsein; Clifford J Rosen; Charles H Turner; Cheryl L Ackert; Kathryn L Shultz; Leah Rae Donahue; Gary Churchill; Martin L Adamo; David R Powell; Russell T Turner; Ralph Muller; Wesley G Beamer
Journal:  J Bone Miner Res       Date:  2002-04       Impact factor: 6.741

Review 5.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.

Authors:  S Mohan; D J Baylink
Journal:  J Endocrinol       Date:  2002-10       Impact factor: 4.286

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance.

Authors:  Martin Haluzik; Shoshana Yakar; Oksana Gavrilova; Jennifer Setser; Yves Boisclair; Derek LeRoith
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

8.  Changes of serum levels of osteocalcin, alkaline phosphatase, IGF-I and IGF-binding protein-3 during fracture healing.

Authors:  Tatsuhumi Taniguchi; Tomoko Matsumoto; Hiroyuki Shindo
Journal:  Injury       Date:  2003-07       Impact factor: 2.586

9.  Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo.

Authors:  Alison J Butt; Kristie A Dickson; Fiona McDougall; Robert C Baxter
Journal:  J Biol Chem       Date:  2003-05-30       Impact factor: 5.157

10.  Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.

Authors:  Kristine M Wiren; Anthony A Semirale; Xiao-Wei Zhang; Adrian Woo; Steven M Tommasini; Christopher Price; Mitchell B Schaffler; Karl J Jepsen
Journal:  Bone       Date:  2008-05-16       Impact factor: 4.398

View more
  55 in total

1.  Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation.

Authors:  P M Yamada; H H Mehta; D Hwang; K P Roos; A L Hevener; K W Lee
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  The acid-labile subunit is required for full effects of exogenous growth hormone on growth and carbohydrate metabolism.

Authors:  Iori Ueki; Sarah L Giesy; Kevin J Harvatine; Jin Wook Kim; Yves R Boisclair
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

4.  DMP-1-mediated Ghr gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH.

Authors:  Zhongbo Liu; Oran D Kennedy; Luis Cardoso; Jelena Basta-Pljakic; Nicola C Partridge; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  FASEB J       Date:  2015-10-19       Impact factor: 5.191

5.  Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation.

Authors:  Masanobu Fujimoto; Melissa Andrew; Lihong Liao; Dongsheng Zhang; Gozde Yildirim; Patrick Sluss; Bhanu Kalra; Ajay Kumar; Shoshana Yakar; Vivian Hwa; Andrew Dauber
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

Review 6.  Humanin: Functional Interfaces with IGF-I.

Authors:  J Xiao; S-J Kim; P Cohen; K Yen
Journal:  Growth Horm IGF Res       Date:  2016-04-07       Impact factor: 2.372

7.  The insulin-like growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate.

Authors:  J Christopher Fritton; Yuki Kawashima; Wilson Mejia; Hayden-Williams Courtland; Sebastien Elis; Hui Sun; Yinjgie Wu; Clifford J Rosen; David Clemmons; Shoshana Yakar
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

8.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

Review 9.  The Emerging Role of Glucose Metabolism in Cartilage Development.

Authors:  Judith M Hollander; Li Zeng
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

10.  Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice.

Authors:  Yingjie Wu; Hui Sun; Shoshana Yakar; Derek LeRoith
Journal:  Endocrinology       Date:  2009-06-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.